Can artery scans let high-risk diabetes patients stop blood thinners sooner?
NCT ID NCT07238764
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether people with diabetes and a high risk of bleeding can safely stop taking two blood thinners (DAPT) just one month after getting a special stent, instead of the usual six months. Doctors used a special camera (OCT) to check if the artery had healed enough. The goal was to see if this personalized approach could reduce bleeding without raising the risk of heart attacks or strokes. The study involved 40 participants and compared early stopping to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
polymer-free amphilimus-eluting stent
What this could lead to
If successful, this approach could allow high-risk patients to stop dual antiplatelet therapy earlier, reducing bleeding risk while still preventing clots.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply to all patients. The imaging-guided strategy may not prove as safe as standard care in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Almazov National Medical Research Center of the Ministry of Health of the Russian Federation
Saint Petersburg, 197341, Russia